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Abstract
Genetic loci on New Zealand Black (NZB) chromosomes 1 and 13 play a significant role in the development of lupus-like
autoimmune disease. We have previously shown that C57BL/6 (B6) congenic mice with homozygous NZB chromosome 1
(B6.NZBc1) or 13 (B6.NZBc13) intervals develop anti-nuclear antibodies and mild glomerulonephritis (GN), together with
increased T and B cell activation. Here, we produced B6.NZBc1c13 bicongenic mice with both intervals, and demonstrate
several novel phenotypes including: marked plasmacytoid and myeloid dendritic cell expansion, and elevated IgA
production. Despite these changes, only minor increases in anti-nuclear antibody production were seen, and the severity of
GN was reduced as compared to B6.NZBc1 mice. Although bicongenic mice had increased levels of baff and tnf-a mRNA in
their spleens, the levels of IFN-a-induced gene expression were reduced. Splenocytes from bicongenic mice also
demonstrated reduced secretion of IFN-a following TLR stimulation in vitro. This reduction was not due to inhibition by TNF-
a and IL-10, or regulation by other cellular populations. Because pDC in bicongenic mice are chronically exposed to nuclear
antigen-containing immune complexes in vivo, we examined whether repeated stimulation of mouse pDC with TLR ligands
leads to impaired IFN-a production, a phenomenon termed TLR tolerance. Bone marrow pDC from both B6 and bicongenic
mice demonstrated markedly inhibited secretion of IFN-a following repeated stimulation with a TLR9 ligand. Our findings
suggest that the expansion of pDC and production of anti-nuclear antibodies need not be associated with increased IFN-a
production and severe kidney disease, revealing additional complexity in the regulation of autoimmunity in systemic lupus
erythematosus.
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Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoim-
mune disease of unknown etiology. One of the hallmarks of this
condition is the loss of tolerance to self-antigens, particularly
nuclear Ag, leading to production of anti-nuclear antibodies
(ANA) and formation of immune complexes (IC) [1]. Deposition of
these IC in the glomeruli, skin, joints, and other organs induces
tissue damage resulting in the manifestations of disease including;
glomerulonephritis (GN), skin rash, and arthritis [2].
The New Zealand Black (NZB) mouse and its F1 cross with the
New Zealand White mouse (NZB/W) closely mimic SLE and
characterization of the immune defects in these mice has led to a
number of fundamental insights into the human disease [3]. To
facilitate identification of NZB lupus susceptibility loci, we have
produced congenic mouse strains, in which homozygous NZB
chromosomal intervals containing a single or cluster of suscepti-
bility alleles have been introgressed onto the non-autoimmune
C57BL/6 (B6) background. We have previously shown that
congenic mice with NZB chromosome 1 (B6.NZBc1) or chromo-
some 13 (B6.NZBc13) intervals develop ANA and mild GN [4–5].
In both mouse strains, this was accompanied by several cellular
phenotypic abnormalities including splenomegaly and increased
proportions of activated T and B cells; however, the nature of the
autoantibody (autoAb) produced and immune defects in these
mice differed [5–6]. B6.NZBc1 mice demonstrate a breach of
tolerance to nuclear antigens that is characterized by the presence
of histone-reactive T cells and high levels of IgG anti-chromatin, -
ssDNA and -dsDNA antibodies [6], whereas B6.NZBc13 have
impaired macrophage clearance of apoptotic debris and produce
predominantly IgM and IgG anti-chromatin antibodies ([5],
manuscript in preparation). In this study, we examined
B6.NZBc1c13 bicongenic mice that contain both chromosomal
intervals. Although these mice were originally produced to
investigate the impact of genetic interactions between these loci
on autoimmune phenotypes, the most striking finding in these
mice was the marked expansion of their splenic myeloid (mDC)
and plasmacytoid DC (pDC) populations. Despite these changes,
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severity of GN was reduced as compared to B6.NZBc1 mice.
As production of type I interferons (IFN) by IgG nuclear-
antigen containing IC-stimulated plasmacytoid dendritic (pDC)
has been proposed to play an important pathogenic role in SLE
[7], we examined whether increased levels of IFN-a were seen in
bicongenic mice. Surprisingly, splenic IFN-a levels remained low
in bicongenic mice and production of IFN-a by pDC appeared to
be reduced in older mice. This reduction in IFN-a production was
not due to inhibition by other cytokines, such as TNF-a and IL-10,
or regulation by other cellular populations. Instead, the pDC of
older mice appeared to be refractory to TLR activation. Notably,
both B6 and bicongenic bone marrow-derived pDC became
refractory to TLR activation following repetitive stimulation with
TLR ligands in vitro, demonstrating reduced secretion of IFN-a.
This finding suggests that the lack of IFN-a production in vivo
might arise from chronic activation due to nuclear antigens in the
environment. Our results indicate that chronic exposure of pDC to
IgG anti-nuclear IC does not necessarily lead to enhanced IFN-a
production, and suggests that additional factors contribute to the
abnormal production of IFN-a in human SLE.
Results
B6.NZBc1c13 mice demonstrate a dramatic expansion of
DC populations
We have previously shown that B6.NZBc1 and/or B6.NZBc13
mice have a number of cellular abnormalities including splenomeg-
aly,increasedBandTcellactivation,andexpansionofmDC[4–5].
Therefore, the impact of genetic interactions between loci on
chromosomes 1 and 13 on these phenotypes was assessed in
bicongenic mice. As shown in Table 1, the splenic weight and
number of splenocytes were significantly greater in 8-month-old
bicongenic mice than their monocongenic counterparts, indicating
that chromosomes 1 and 13 loci contribute additively to this
phenotype.
While the proportions of B220
+, CD4
+, CD8
+ and
CD11b
+CD11c
2 cells were similar in bicongenic mice to those
observed in one or both monocongenic mouse strains, there was a
marked increase in the proportion of CD11c
+ cells (Table 1). In
bicongenic mice, the proportion of CD11c
+ cells was increased ,2
fold as compared to both monocongenic strains and represented
almost a quarter of splenocytes. To further characterize the
phenotype of the expanded CD11c
+ population(s), splenocytes
were stained with anti-CD11c Ab together with anti-B220 and -
NK1.1, or anti-CD11b to identify CD11c
+B220
+NK1.1
2 pDC or
CD11c
+CD11b
+ mDC, respectively. As shown in Figure 1,
expansions of both pDC and mDC compartments contributed
to the increased proportion of DC in bicongenic mice. This
increase was most pronounced for pDC where there was a ,5 fold
increase in bicongenic mice as compared to monocongenic mice.
As previously reported [8], increases in the splenic pDC and mDC
compartment were not seen in NZB mice, suggesting that
additional genetic loci present in NZB mice suppress this
phenotype.
Expansion of the pDC population was not seen in the bone
marrow of 8-month-old bicongenic mice (%CD11c
+B220
+NK1.1
2
cells, B6=2.85%61.34, n=13; B6.NZBc1=2.72%61.41, n=18;
B6.NZBc13=2.79%61.51, n=4; B6.NZBc1c13=2.29%61.44,
n=17; NZB=2.34%61.09, n=6; all p.0.05 as compared to B6
mice). However, moderate expansion of the bone marrow mDC
compartment was observed (%CD11c
+CD11b
+ cells,
B6=2.20%61.24, n=13; B6.NZBc1=4.01%61.68, n=18,
p=0.0035; B6.NZBc13=2.44%61.35, n=4, p.0.05;
B6.NZBc1c13=5.57%63.29, n=17, p=0.0002;
NZB=1.69%60.59, n=6, p.0.05, all p values as compared to
B6). Differences in the proportions of pDC and mDC in the spleen,
andformDCinthebonemarrow,werealreadyseenin2-month-old
B6.NZBc1c13 mice but were much less marked (spleen pDC,
B6=0.79%60.33, n=9; B6.NZBc1c13=1.34%60.47, n=11;
p,0.05; spleen mDC, B6=2.53%60.86, n=9;
B6.NZBc1c13=5.33%61.49, n=11; p,0.0005; bone marrow
Table 1. Comparison of the splenic phenotype in 8 month old B6.NZBc1c13 bicongenic mice with B6.NZBc1 and B6.NZBc13
congenic strains.
B6 B6.NZBc1 B6.NZBc13 B6.NZBc1c13 NZB
N=18 N=28 N=9 N=31 N=9
Spleen weight (mg) 109.5633.8 222.4±56.7
*** 246.4±130.9
** 376.5±161.1 508.9±310.6
# Splenocytes (610
6) 58.94619.45 100.3±48.32
* 83.28±25.25
* 131.8±65.49 136.5±84.07
% B220
+ 56.4869.02 58.1668.28 59.7867.61 51.65610.01 29.25±12.49
***
% CD21
lowCD23
2 6.9762.33 8.1463.05 8.46±2.59 7.6963.26 9.35±2.63
% CD21
intCD23
+ 38.61610.09 40.4969.15 35.3668.03 34.15611.90 10.58±6.06
***
% CD21
hiCD23
+ 2.8661.75 2.6061.68 2.5261.60 2.3461.32 0.30±0.38
***
% CD21
hiCD23
2 3.6761.22 2.36±1.66 6.20±2.96
*** 1.69±0.81 1.58±1.47
% CD4
+ 19.6863.96 20.6162.76 18.7763.25 20.7063.75 23.1665.00
% CD8
+ 10.9165.43 6.67±3.41 8.9661.13
* 5.77±2.18 6.07±2.61
% CD11c
+ 10.3364.47 (14) 14.3666.53
** (21) 12.9164.69
* 23.22±9.81 (23) 10.6661.34
***
% CD11b
+CD11c
2 2.3861.06 (11) 3.5261.45 (13) 1.5460.73 (4) 2.4261.08 (11) 11.59±8.25* (8)
Results are mean 6 SD as determined by weight or flow cytometry. Significance level for comparison of B6.NZBc1c13 mice with other mouse strains was determined by
Mann-Whitney non-parametric test,
*p,0.05,
**p,0.005,
***p,0.0005. Numbers of 8 month old mice examined in each group are shown on the top unless otherwise indicated in brackets. Numbers shown in bold indicate
significant difference p,0.05 from B6 control mice.
doi:10.1371/journal.pone.0036761.t001
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n=8; p.0.05 ; bone marrow mDC, B6=2.37%60.29, n=6;
B6.NZBc1c13=3.36%61.15, n=8; p,0.05).
We have previously shown that 8-month-old B6.NZBc13 mice
have B cell phenotypic changes similar to 4-month-old NZB mice,
with reduced proportions of follicular (CD21
intermediate(int)CD23
+)
and increased proportions of MZ (CD21
high(hi)CD23
2) and B1a
(CD21
low(lo)CD5
+) B cells [5]. Surprisingly, in contrast to the DC
changes, these phenotypes were not more pronounced in the
bicongenic mice (Table S1). Indeed, B6.NZBc1c13 mice had
reduced proportions of MZ B cells similar to B6.NZBc1 mice. This
wasnotduetoanage-associatedlossoftheMZBcellpopulation (as
seen in NZB mice), because 4-month-old bicongenic mice demon-
strated a similar reduction in their MZ B cell population
(%CD21
hiCD23
2 cells, B6=5.89%60.98, n=15;
B6.NZBc1=3.98%61.84, n=9, p=0.0200;
B6.NZBc13=9.76%61.47, n=2, p=N.D.;
B6.NZBc1c13=4.38%61.90, n=11, p=0.0430, all p values as
Figure 1. Expansion of dendritic cell populations in the bicongenic mice. Freshly isolated splenocytes from 8 month old female B6,
B6.NZBc1, B6.NZBc13, B6.NZBc1c13 and NZB mice were stained with anti-CD11c in combination with anti-B220 and -NK1.1 or anti -CD11b antibodies
to assess the proportion of plasmacytoid and myeloid DC. Shown are the (A) absolute number of splenic CD11c
+ DC, and proportion of (B)
B220
+CD11c
+NK1.1
2 pDC and (C) CD11b
+CD11c
+ mDC. Each symbol represents the determination from an individual mouse. Horizontal lines indicate
the mean for each population examined. The p values for significant differences between the congenic mouse strains are shown above bars, whereas
asterisks represent significant differences between various congenic mice and B6 controls, *p,0.05, **p,0.005, ***p,0.0005. (D) Representative dot
plots show the gating regions for NK1.1
2 gated B220
+CD11c
+ pDC (top panel) and CD11b
+CD11c
+ mDC (bottom panel). Numbers inside the box
indicate the proportion of each population.
doi:10.1371/journal.pone.0036761.g001
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contaminating B220
+ pDC, because the same changes were seen
when this population was expressed as a proportion of total
splenocytes (data not shown). Similar findings were observed for the
splenic B1a cell population, where the proportion of cells in 8-
month-old bicongenic mice was similar to that observed in
B6.NZBc1 mice and was significantly reduced as compared to both
B6.NZBc13 and NZB mice. Thus, the distribution of B cells in
bicongenic mice appears to be driven predominantly by genetic loci
onNZBchromosome1,whereasgeneticlocionchromosomes1and
13 interact additively to produce marked DC expansion in
bicongenic mice.
Given the expansion of DC in bicongenic mice and the
potential role of these populations in stimulation of B and T cells,
we examined whether activation of these populations was
increased in bicongenic mice. As shown in Table S1, activation
of the CD21
int, predominantly follicular, and CD21
hi, precursor
and mature MZ, B cell compartments was similar in bicongenic
mice to that in parental monocongenic mouse strains. We were
not able to examine activation in the CD21
lo B cell compartment,
because this population was contaminated with pDC in our stains.
The proportions of recently activated CD69
+ and memory/
effector CD44
hiCD62L
lo CD4
+ T cells in bicongenic mice were
also not increased as compared to B6.NZBc1 mice. These findings
indicate that the expansion of DC in bicongenic mice does not
appear to lead to enhanced B or T cell activation.
Clinical autoimmune disease is not amplified in
bicongenic mice despite altered autoAb production
To determine whether the expansion of DC in bicongenic mice
is associated with more severe disease, autoAb levels and kidney
disease were contrasted between the monocongenic and bicon-
genic mouse strains. Six- to 7-month-old B6.NZBc1 congenic mice
produce significantly higher titers of IgG anti-histone, -chromatin
and -ssDNA Ab than age-matched B6 controls, whereas IgM and
IgG anti-chromatin Ab are predominantly produced in
B6.NZBc13 mice [4–5]. As shown in Figure 2A, bicongenic mice
demonstrated features of both strains, with elevated levels of IgG
autoAb that approximated those seen in the B6.NZBc1 mouse
strain and the increased levels of IgM anti-chromatin Ab seen in
the B6.NZBc13 strain. In general, the levels of IgM autoAb in
bicongenic mice exceeded those seen in the monocongenic mouse
strains, which achieved statistical significance for anti-chromatin
Ab. However, with the exception of anti-chromatin Ab, the levels
of IgM autoAb remained lower than those seen in NZB mice.
Notably, B6.NZBc1c13 mice produced moderate to high titers of
IgA anti-chromatin Ab and low titers of IgA anti-ssDNA and -
dsDNA Ab, which were markedly increased as compared to those
seen in the monocongenic mice. Thus, genetic interactions
between NZB chromosomes 1 and 13 result in the novel
generation of IgA ANA.
Despite the development of these novel autoAb phenotypes and
levels of IgG ANA similar to those observed in B6.NZBc1 mice,
light microscopic changes and the amount of IgG deposition in the
kidneys of bicongenic mice were significantly reduced compared to
B6.NZBc1 and were similar to those observed for B6.NZBc13
mice (Figure 2B–C). Furthermore, although NZB chromosome 1
is reported to contain a genetic locus that facilitates anti-RBC Ab
production in crosses with other lupus susceptibility loci [9], anti-
RBC Abs were not produced in either B6.NZBc1 or
B6.NZBc1c13 mice (%RBC IgM
+, B6=1.39%60.95 n=4;
B6.NZBc1=2.10%60.87, n=7; B6.NZBc1c13=2.23%60.92,
n=8; all p.0.05 as compared to B6: %RBC IgG
+,
B6=0.67%60.29, n=4; B6.NZBc1=0.73%60.46, n=7;
B6.NZBc1c13=0.77%60.26, n=8; all p.0.05 as compared to
B6). Taken together, these findings indicate that the expansion of
DC in bicongenic mice is not associated with a significant increase
in the severity of the clinical disease phenotype.
In vivo cytokine production in bicongenic mice
One of the consequences of DC activation is the production of
cytokines. Given the dichotomy between the expansion of the DC
subsets and lack of exacerbated clinical autoimmunity in
bicongenic mice, we examined the production of several pro-
inflammatory cytokines, BAFF, TNF-a, and IFN-a, which are
produced by DC and have been shown to play an important role
in autoimmunity [10–12]. Since serum BAFF levels correlate
poorly with BAFF production [13], splenic BAFF production was
assessed by the measurement of baff mRNA levels using qRT-PCR
and BAFF protein expression assessed using immunofluorescence
microscopy. There was a ,6 fold increase in baff mRNA levels in
bicongenic as compared to B6 mice (Figure 3A, B6=2.5862.24,
n=12; B6.NZBc1c13=14.93620.31, n=8), which was not seen
in the parental congenic strains. Consistent with this observation,
there were increased numbers of BAFF-producing cells in the
spleens of bicongenic mice that were predominantly mDC (Figure
S1). Similar to BAFF, there were increased levels of tnf-a mRNA in
the spleens of bicongenic as compared to B6 mice (Figure 3A).
However, the increase in tnf-a levels was only ,2 fold
(B6=0.4360.17, n=9; B6.NZBc1c13=0.8160.45, n=8). This
appeared to arise from the B6.NZBc13 parental strain.
In contrast to BAFF and TNF-a, splenic levels of type I IFN and
IFN-a-induced genes were normal or reduced in 8-month-old
bicongenic as compared to B6 mice (Figure 3B). Similar findings
were seen in the B6.NZBc1 parental strain. Thus, although pDC,
the major producers of type I IFN, are increased in 8-month-old
bicongenic mice,thelevels of typeI IFNare notincreased. The lack
of increased type I IFN and IFN-inducible gene expression in
bicongenic mice was not due to insensitivity of the RT-PCR assay,
because all of the values were well above the threshold of detection.
A similar lack of increased expression of type I IFN or IFN-a-
induced genes was also observed in the spleens of younger
bicongenic mice (2-month-old) as well as the kidney and bone
marrow of 9-month-old mice (Figure S2). However, a significant
increase in 29-59 oas was seen in the bone marrow of 2 month-old
bicongenic mice.
Reduced in vitro cytokine production by pDC from
bicongenic mice
Inlupus,pDCuptakeofIgGICcontainingDNAorRNA,results
in TLR engagement and secretion of IFN-a [7,14–16]. Thus, the
relative absence of IFN-a secretion in bicongenic mice could reflect
reduced activation of these cells as a consequence of low levels of
anti-nuclear IC or an impaired ability of pDC to be stimulated by
these complexes. Since bicongenic mice have increased levels of
ANA and deposition of IC in their kidneys, it seemed unlikely that
the absence of pDC IFN-a secretion in older mice resulted from a
lack of IC; therefore, the ability of pDC to respond to TLR
stimulation was assessed. To this end, freshly isolated splenocytes
from8-week-and8-month-oldmicewereincubatedwiththeTLR9
ligand, CpG 2216, which has been shown to induce IFN-a and
TNF-asecretionbypDC[17],orCpG1826,whichhasbeenshown
to induce TNF-a and IL-10 secretion in a variety of cell types, as a
control(Figure4).Althoughtherewasconsiderablevariabilityinthe
ability of splenocytes to secrete IFN-a following stimulation with
CpG 2216 in both mouse strains, IFN-a production was generally
reduced in bicongenic as compared to B6 mice. This was most
markedin8montholdmice,wherereducedlevelswereseendespite
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36761Figure 2. AutoAb levels and renal involvement in various congenic mouse strains. (A) Serum samples from 8 month old female B6,
B6.NZBc1, B6.NZBc13, B6.NZBc1c13 and NZB mice were assayed for the presence of total IgM, IgG and IgA as well as IgM, IgG or IgA anti-chromatin, -
ssDNA and -dsDNA Ab. (B) Immunofluorescence scores of frozen kidney sections stained with anti-IgG. Sections were graded as follows: grade 0, no
or only trace deposits; grade 1, mesangial deposits (B more extensive than A); grade 2, mesangial and segmental capillary wall deposits; grade 3,
diffuse mesangial and capillary wall deposits; grade 4, crescents. (C) Glomerular scores of kidneys fixed in formalin, paraffin embedded, sectioned, and
stained with PAS. Sections were graded as: grade 0, normal glomeruli; grade 1, mesangial expansion and/or proliferation; grade 2, focal segmental
proliferative glomerulonephritis; grade 3, diffuse proliferative glomerulonephritis; and grade 4, diffuse proliferative glomerulonephritis with crescents.
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variations in cytokine production between mice were not due to
variations in the proportions of pDC, as reduced IFN-a secretion
was seen in bicongenic mice with increased proportions of pDC,
indicating reduced production on a per cell basis. Furthermore,
reduced IFN-a secretion was still seen in some bicongenic mice
when DC were isolated by positive selection (Figure 4C). Secretion
of TNF-a by pDC was also reduced but this did not achieve
statistical significance (Figure 4A). In contrast to the findings with
CpG 2216, secretion of TNF-a and IL-10 secretion following CpG
1826 stimulation was preserved in 8 month-old bicongenic mice
(Figure 4B).
To determine whether an intrinsic DC functional abnormality
leadstothealteredsecretionofIFN-abysplenicDCstimulatedwith
CpG 2216, bone marrow cells were obtained from 8–12-week-old
B6 and pre-autoimmune bicongenic mice and cultured in the
presence of Flt3L for 7 days to expand bone marrow-derived DC
(BMDC). Although there were similar proportions of mDC and
pDC in the bone marrow of young B6 and bicongenic mice pre-
culture, and similar numbers of BMDC post-culture, there was a
slight increase in the proportion of pDC and decrease in the
proportion of mDC in BMDC cultures from bicongenic as
compared to B6 mice (% pDC, B6=41.44%61.20, n=5;
B6.NZBc1c13=46.33% 62.64, n=5, p=0.0278; % mDC,
B6=38.77%62.31, n=5; B6.NZBc1c13=31.10%61.12,
p=0.0079). Immediately following expansion, basal levels of TLR
(TLR3, TLR7, TLR9), MHCII, and B7.2 molecules were found to
be similar for pDC and mDC derived from both strains (data not
shown). Furthermore, BMDC from B6 and B6.NZBc1c13 mice
producedsimilaramountsofIFN-aandIL-10followingstimulation
with various TLR ligands, but demonstrated minor differences in
the secretion of TNF-a with R837 and CpG 1826 (Fig. S3A–C).
pDC from these strains of mice also demonstrated similar
upregulation of B7.2 following stimulation with the TLR ligands
(Fig.S3E).Incontrast,B7.2upregulationwiththeTLR3ligandpoly
I:C and TLR9 ligands CpG 1826 and 2216 was reduced in mDC
(Fig. S3F). Thus, pDC from BMDC appear to function normally,
whereas some minor functional differences in mDC were observed
between the two mouse strains. These findings suggest that the
altered function of splenic pDC in bicongenic mice develops in
response to the bicongenic environment.
Each symbol represents the determination from an individual mouse. Horizontal lines indicate the mean for each population examined. The p values
for significant differences between the congenic mouse strains are shown above bars, whereas asterisks represent significant differences between the
various congenic mice and B6 controls, *p,0.05, **p,0.005, ***p,0.0005.
doi:10.1371/journal.pone.0036761.g002
Figure 3. Production of excess BAFF and TNF-a, but reduced levels of IFN-a in the spleens of B6.NZBc1c13 mice. (A) Increased BAFF
and TNF-a mRNA expression in B6.NZBc1c13 (c1c13) and B6.NZBc13 (c13) splenocytes and (B) reduced IFN- a/b and IFN-a-induced gene (PKR and 29-
59 OAS) expression in c1c13 and B6.NZBc1 (c1) splenocytes. Relative mRNA expression of genes of interest normalized to b-actin mRNA expression in
freshly isolated splenocytes from 8-month-old female mice. Each point represents the determination from an individual mouse. The p values for
significant differences between various congenic mice and B6 controls and various congenic mice are shown, *p,0.05, **p,0.005, as determined by
Mann-Whitney non-parametric test.
doi:10.1371/journal.pone.0036761.g003
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cytokine or cellular inhibition
Both IL-10 and TNF-a have been shown to inhibit IFN-a
secretionbypDC[19–20],thereforeitispossiblethatelevatedlevels
of these cytokines in bicongenic mice inhibit IFN-a production. To
investigate this possibility, IFN-a production was assessed in
splenocyte cultures that were stimulated with CpG 2216 in the
presence or absence of blocking antibodies against TNF-a and/or
IL-10. As shown in Figure 5A and 5B, IL-10 blockade leads to a
slight increase in IFN-a production in some mice, however this was
similar in B6 and B6.NZBc1c13, and present in both young and old
mice. In contrast, TNF-a blockade resulted in a slight decrease in
IFN-a production in some mice. Blockade of both cytokines did not
result in further augmentation of IFN-a production in either young
or old mice. Thus, the reduction in IFN-a production by the
splenocytes of older B6.NZBc1c13 mice does not appear to arise
from inhibition by these cytokines.
Figure 4. Reduced IFN-a, but not TNF-a and IL-10 production following stimulation of splenocytes with TLR ligands in bicongenic
mice. Freshly isolated splenocytes from 8 week or 8 month old female B6 or B6.NZBc1c13 (c1c13) mice were stimulated with (A) CpG 2216 or (B) CpG
1826 for 48 h. Stimulation with CpG 2216 control or CpG 1826 control did not show differences between B6 and c1c13 mice (data not shown). (C)
CD11c
+ splenic DC from B6 and c1c13 mice were stimulated with CpG 2216 for 24 h. Levels of IFN-a, TNF-a and IL-10 in the culture supernatants were
determined using ELISA. Each symbol represents the determination from an individual mouse. The p values for significant differences between B6
and B6.NZBc1c13 mice are shown above bars.
doi:10.1371/journal.pone.0036761.g004
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production of IFN-a by IgG IC-stimulated human pDC in vitro
[21], we assessed whether splenocytes from older mice that
demonstrated reduced production of IFN-a in vitro could inhibit
production of IFN-a by splenocytes from young mice. To this end,
splenocytes from young and old mice were mixed (1:1) and IFN-a
production was assessed following stimulation with ODN 2216
(Fig. 5C). In mixed cultures, cytokine production exceeded the
average of those seen for splenocytes from young and old mice for
both B6 and B6.NZBc1c13 strains, indicating that old cells were
not inhibiting IFN-a production by young splenocytes. These
findings suggest that other factors may be causing the reduced IFN
production in old bicongenic mice.
Bone marrow-derived pDC from bicongenic mice
demonstrate normal cytokine production and tolerance
following TLR stimulation in vitro
Previous work on human pDC indicates that IFN-a secretion is
inhibited by repetitive stimulation with TLR ligands or Ig IC-
containing nuclear antigens, a phenomenon that has been termed
TLR tolerance [22–23]. Thus, given the high titers of ANA
together with the evidence of IC deposition in bicongenic mice, it
is possible that the pDCs from older bicongenic mice are
refractory to TLR stimulation as a consequence of chronic
stimulation by IgG nuclear antigen-containing IC. To explore this
possibility, we examined activation of BMDC following single and
repetitive stimulation with CpG 2216. To this end, BMDC were
cultured for 24 hours in the presence or absence of CpG 2216,
washed and then stimulated again with CpG 2216. Supernatants
were harvested at 24 (before washing) and 48 hours, with cell
viability and cellular activation (upregulation of B7.2) being
measured at the endpoint by flow cytometry (Fig. 6A). Although
pDC stimulated after 24 hours secreted significantly lower levels of
IFN-a than those stimulated at the onset of culture period, the
levels of IFN-a secreted by pDC from all mouse strains tested were
comparable (Fig. 6B). Notably, IFN-a secretion in the second 24-
hour period of culture was completely abrogated by incubation
with CpG 2216 in the first 24 hours, with similar findings for B6
and B6.NZBc1c13 pDC. In contrast, B7.2 expression was
maintained or further increased by a second stimulation with
CpG 2216, suggesting that the cells are not refractory to activation
but that cytokine secretion may be specifically inhibited (Fig. 6C).
The reduced cytokine production was not secondary to reduced
cell viability because the proportion of live cells was similar in both
cultures. Thus, murine pDC like their human counterparts,
demonstrated impaired IFN-a production following repeated TLR
stimulation and this process is intact in bicongenic mice.
Splenic pDC in older bicongenic mice have a phenotype
suggesting chronic activation in vivo
The findings outlined above raised the possibility that chronic
stimulation of pDC by nuclear antigen-containing IC in bicon-
genic mice leads to their failure to secrete IFN-a in bicongenic
mice. To address this possibility, expression of B7.2 and MHC
Class II (MHC II), two molecules that are increased with
activation, was examined in freshly isolated splenocytes from
young and old mice. Since the CD11c
+ B220
+ NK1.1
2 population
that was used to gate pDC could be contaminated with age-
associated B cells (ABCs), which have been shown to express
similar markers and express high levels of B7.2 and MHC II,
additional stains were performed to determine the proportion of
these cells within the gated population and to enable examination
of activation of pDC in the absence of the contaminating ABCs
[18]. By definition the ABC subset is CD11c
intCD11b
int and
expresses CD19 and IgM. Approximately 10–20% of the cells
gated within the conventional pDC gate expressed these markers,
which was similar for both B6 and bicongenic, young and old mice
(Fig. S4A). An increased proportion of pDC (CD11c
+ B220
+
CD11b
2) was still seen in old bicongenic mice when CD11b
+ cells,
including the ABC subset, were excluded from the analysis (Fig.
S4B). As shown in Figure 7A, increased levels of MHC II, but not
B7.2, were seen on the pDC of older bicongenic mice, using this
more restrictive gating.
Interestingly, the ABC subset was also elevated in older
bicongenic mice (Fig. S4C–D).
Previous studies have also shown that there are distinct
subpopulations within the pDC subset that vary in their capacity
Figure 5. Cytokines or other cellular populations do not inhibit
IFN-a production by CpG 2216 stimulated splenocytes from
older c1c13 bicongenic mice. Freshly isolated splenocytes from (A) 8
week or (B) 8 month old female B6 or B6.NZBc1c13 (c1c13) mice were
stimulated with CpG 2216 for 48 h in the presence or absence of anti-IL-
10 and anti-TNF-a blocking antibodies. Levels of IFN-a in the culture
supernatants were determined using ELISA. Each symbol represents the
determination from an individual mouse. (C) Freshly isolated spleno-
cytes from 8 to 12 week (young) and 8 month (old) B6 or c1c13 mice
were stimulated alone or mixed at a 1:1 ratio with CpG 2216 for 48 h.
Levels of IFN-a production were determined by ELISA. The dotted lines
represent the average IFN-a production by the young and old
splenocytes when stimulated separately by CpG 2216. Shown in the
figure are representative mice from two separate experiments.
doi:10.1371/journal.pone.0036761.g005
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bicongenicmicetosecreteIFN-afollowingstimulationmightreflect
over-representation of pDC populations that cannot secrete IFN-a.
To examine this possibility, freshly isolated splenocytes from young
and old mice were stained with anti-CD11c, B220, CD11b, IgM,
and CD19, to permit gating of pDC free of ABCs, in tandem with
anti-CD9andSiglecH.IthasbeenshownthatthelessmatureCD9
+
SiglecH
2 pDC can secrete IFN-a, whereas the more mature
SiglecH
+ CD9
2 pDC cannot [24]. As shown in Figure 7B and 7C,
older bicongenic mice have an increased number and proportion of
immature pDC, a phenotype suggesting they should have the
capacity to secrete IFN-a. The PDCA-1 staining in these each of
these populations, was similar to that previously reported, and did
not differ between the mouse strains (Figure 7D). Notably, both the
CD9
+ SiglecH
2 and SiglecH
+ CD9
2 subpopulations of pDC
showed evidence of increased activation in older bicongenic mice
(Figure7E&7F).AsshowninFigure7G&7H,increasedexpression
of B7.2 and MHC II was seen also in the CD11b
2 subset of these
subpopulations. Thus, the reduced levels of IFN-a in bicongenic
mice appear to result from an impaired ability of previously
stimulated immature pDC to secrete IFN-a.
Figure 6. TLR tolerance impacts on IFN-a production, but not B7.2 upregulation, in BMDC from B6 and c1c13 bicongenic mice after
repeated TLR9 stimulation. (A) Experimental design to investigate TLR tolerance of BMDC to TLR9. BMDC were cultured for 24 hours in the
presence or absence of CpG 2216, washed and then stimulated again with CpG 2216. Supernatants were harvested at 24 (before washing) and
48 hours, and cellular profiles were assessed by flow cytometry after 48 hours. (B) IFN-a production by stimulated BMDC was measured by ELISA and
(C) the mean fluorescence intensity (MFI) for B7.2 expression was quantified in various DC subsets (CD11c
+ DC, CD11c
+B220
+CD11b
2 pDC and
CD11c
+CD11b
+B220
2 mDC) using flow cytometry. Each symbol represents the determination from an individual female B6, B6.NZBc1 (c1), B6.NZBc13
(c13) or B6.NZBc1c13 (c1c13) mouse. Horizontal lines indicate the mean for each population examined. The p values for significant differences
between various congenic mice and B6 control mice are shown, *p,0.05,* * p,0.005.
doi:10.1371/journal.pone.0036761.g006
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In this paper, bicongenic mice with NZB chromosome 1 and 13
intervals were produced to determine whether genetic interactions
between these two chromosomes lead to exacerbated autoimmu-
nity. While autoimmunity was not more pronounced in these mice
than in parental monocongenic strains, several novel phenotypes
were seen that were either absent in the monocongenic strains or
markedly exacerbated in bicongenic mice. These included
dramatic increases in the size of the mDC and pDC populations,
and elevated levels of total and anti-nuclear IgA antibodies.
Although there are small but significant increases in the
proportions of mDC and pDC for B6.NZBc1 and mDC in
B6.NZBc13 mice, these were markedly augmented in the bicon-
genic mice. As yet, the precise mechanisms leading to this increased
expansion in bicongenic mice have not been determined. However,
similar expansions of these subsets have been seen in mice with
increased TLR responses and/or impaired clearance of apoptotic
debris such as TLR7 transgenic [25], Tir8 knockout [26], and
Mer
Kd [27] mouse strains. Increased TLR signaling can produce
expansion of DC populations either by directly inducing activation
or migration of DC into the spleen [28–29], or indirectly by
increasingpro-inflammatoryfactorsthathavebeenshowntorecruit
and/or promote survival of DC [30–32]. It is likely that the
expansion of DC in bicongenic mice results from a combination of
these factors. Recent experiments in our laboratory indicate that
B6.NZBc13 mice have a defect in clearance of apoptotic debris by
macrophages, resultinginincreased availabilityofTLR-stimulating
nuclearantigens(manuscriptinpreparation).AlthoughsplenicpDC
frommicewithashorterNZBchromosome1intervalencompassed
within the interval studied here have been reported to secrete
augmented levels of IFN-a and IL-10 in response to TLR-9
stimulation suggesting an increased TLR response [33], this
phenotype was not seen in bicongenic mice. However, bicongenic
mice have increased amounts of a variety of pro-inflammatory
factors including IFN-c, TNF-a and BAFF, raising the possibility
that the expansion of DC in these mice may arise from increased
amounts of pro-inflammatory factors rather than TLR-hyper-
responsiveness. It is possible that this capacity to produce pro-
inflammatory factors arises from genetic loci on chromosome 1, as
increased levels of these cytokines, with the possible exception of
TNF-a, were not seen in B6.NZBc13 mice. Thus, the expansion of
pDC and mDC in bicongenic mice may arise from increased
amounts of apoptotic debris arising from a genetic locus on NZB
chromosome13,actingintandemwithincreasedproductionofpro-
inflammatoryfactorsarisingfromgeneticlocionNZBchromosome
1.
BAFF levels were markedly increased in bicongenic mice as
compared to B6 mice and were at least as high as those seen in
NZB mice. This increase appeared to require genetic loci from
both chromosomes 1 and 13, as it is seen in neither B6.NZBc1 nor
B6.NZBc13 8-month-old mice. In BAFF transgenic mice, there
are increased levels of total serum IgA and IgA autoAb, and BAFF
has been shown to facilitate class switching to IgA production [34–
35]. Thus, it is likely that the increased IgA levels in NZB and
bicongenic mice arise, at least in part, from increased BAFF.
However, the elevated levels of BAFF in bicongenic mice were not
sufficient to overcome the reduction in the MZ B cell population
mediated by genetic loci on chromosome 1. At present, it is
unclear what is driving this BAFF production in bicongenic mice.
Although IFN-a has been shown to enhance BAFF production
[36], the low levels of IFN-a and IFN-induced gene expression in
bicongenic mice suggest that IFN-a does not play a significant role
in BAFF induction. Uptake of circulating Ag, such as apoptotic
debris, has also been shown to promote localization of mDC-like
cells to the spleen [37] and induce their BAFF expression [16,37].
These cells have been shown to localize initially to the MZ, where
they cluster with B cells, inducing their Ab secretion. In bicongenic
mice, BAFF-producing cells are scattered throughout the red pulp
and are not found in clusters with Ab-producing B cells (Figure
S1), however it is possible that their localization in the MZ was a
transient state or that they were already localized in the spleen and
became activated in situ.
Despite the marked expansion of the pDC subset in bicongenic
mice,levelsoftypeIIFNdidnotappeartobeincreased.Thismaybe
relevant to the lack of severe GN in the bicongenic mice, since even
modest increases in IFN-a have been shown to markedly accelerate
kidney disease [10]. Several possible mechanisms were explored for
thelackofIFN-ainolderbicongenicmice.Bothcytokinesanddirect
cellular interactions have been shown to modulate IFN-a secretion
by pDC. However, blocking studies with monoclonal antibodies
directed against TNF-a and IL-10, two cytokines shown to inhibit
IFN-a secretion by pDC [19–20], did not restore the capacity of
pDC from older mice to secrete IFN-a. In mixing experiments,
splenic cellular populations from older mice also had no impact on
IFN-a production by pDC from young mice. Thus, the secretion of
IFN-a in older bicongenic mice does not appear to be actively
suppressed by either cytokines or cellular interactions. Chronic
activationofhumanpDCbyTLRligandshasbeenshowntoleadto
desensitization to TLR-signaling, resulting in impaired production
of IFN-a. To determine whether murine pDC can be rendered
similarlyrefractorytoactivation,BMDCwerestimulatedrepeatedly
with a TLR9 ligand. Similar to their human counterparts, repeated
stimulation of pDC led to markedly impaired IFN-a secretion. This
raised the possibility that chronic stimulation of pDC by nuclear
antigen-containing IC in bicongenic mice leads to their failure to
secrete IFN-a in bicongenic mice. Consistent with this possibility,
pDC of older bicongenic mice showed evidence of previous
activation in vivo,withincreasedexpression ofMHCII,ascompared
toB6mice.Thisincreasedactivationwasseenbothintheimmature
and mature pDC populations. In contrast to MHCII, the levels of
B7.2 were either not or only marginally increased on pDC in older
bicongenic mice. As shown in Figure 6, pDC from bicongenic mice
are impaired in their ability to upregulate B7.2 following TLR
Figure 7. Increased activation of cells in the immature and mature pDC subsets of older bicongenic mice. Expression of the activation
markers (A) B7.2 and MHCII was quantified by mean fluorescent intensity (MFI) on splenic pDC gated as CD11c+ B220+ CD11b2 in 8 week old
(young; Yng) and 8 month old (Old) B6 and bicongenic mice. pDC populations were further characterized with additional surface markers to remove
contaminating IgM+ CD19+ ABCs and to determine the maturity of pDC. Immature (CD9+ SiglecH2) and mature (SiglecH+ CD92) pDC were gated
on the CD11c+ B220+ CD11b2 IgM2 CD192 splenic pDC population and the data expressed as a proportion of total live splenocytes (B) and as a
proportion of total pDC (C). (D) PDCA-1 was highly expressed on mature (SiglecH+ CD92) but not immature (CD9+ SiglecH2) pDC subsets. Elevated
expression of activation markers (E) B7.2 and (F) MHCII was seen in older bicongenic mice in both pDC subsets gated from the CD11c+ B220+ cell
population. Representative histogram plots for older B6 (grey dotted line) and bicongenic mice (solid black line) for (G) B7.2 and (H) MHCII were gated
on the CD11c+ B220+ CD11b2 cells population excluding ABCs, in both the CD9+SiglecH2 and SiglecH+CD92 populations. Results from this figure
show representative data from one of three independent experiments. The p values for significant differences between B6 and bicongenic mice are
shown, *p,0.05.
doi:10.1371/journal.pone.0036761.g007
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lack of increased B7.2 expression in older bicongenic mice could
reflect this signaling difference. Notably, there was an increased
proportionandnumberofimmaturepDCinolderbicongenicmice.
ThisfindingsuggeststhattheimpairedabilityofpDCtosecreteIFN-
a in older bicongenic mice does not result from a decreased
proportionofimmaturepDC,butinsteadappearstoreflecttheprior
activation of these cells in vivo. In further support of the concept, the
only site at which there is evidence of an IFN-a signature in
bicongenic or NZB mice [38] is in the bone marrow, the organ at
which pDC are first exposed to apoptotic debris.
Regardless of the mechanisms leading to impaired IFN-a
secretion in bicongenic mice, the data reported herein indicate
that expansion of pDC and the presence of anti-DNA Ab need not
be associated with increases in IFN-a production. In humans with
SLE, IgG anti-DNA immune complexes have been proposed to
drive the abnormal production of IFN-a by pDC. However, our
findings suggest that there must be additional complexity in the
generation and regulation of IFN-a beyond this mechanism.
Further characterization of these processes may provide important
insights into the immune dysregulation that promotes SLE.
Materials and Methods
Ethics statement
Mice were housed in a Canadian Council on Animal Care
approved facilityat theToronto Western Research Institute, partof
the University Health Network. All mice used and experiments
performed in this study were approved by the Animal Care
Committee ofthe UniversityHealth Network(Animal UseProtocol
#123).
Mice
B6 and NZB mice were purchased from Taconic Farms
(Germantown, NY) and Harlan-Sprague-Dawley (Blackthorne,
England), respectively, and subsequently bred in our facility.
Congenic mice were produced by separately backcrossing NZB
chromosome 1 and 13 intervals onto the B6 background, using the
speed congenic technique [39]. Mice were genotyped at each
successive generation using polymorphic microsatellite markers
that discriminate between NZB and B6 DNA, spaced at ,20 cM
intervals throughout the genome, except for regions containing
lupus susceptibility genes where more densely spaced markers
were used. Fully backcrossed mice were produced within 6 or 7
generations, for chromosome 1 and 13 intervals respectively, and
then intercrossed to produce congenic mice that were homozygous
for the NZB intervals. For NZB chromosome 1 congenic mice
(previously called B6.NZBc1(35-106) but here denoted as
B6.NZBc1 for simplicity) the NZB interval extends from between
rs13475886 (61.2 Mb) and D1Mit303 (63.0 Mb) to between
D1Mit223 (190.5 Mb) and D1Mit210 (192.1 Mb). NZB chromo-
some 13 congenic mice (B6.NZBc13) have an NZB interval
extending from between D13Mit117 (37.7 Mb) and D13Mit92
(46.9 Mb) to D13Mit78 (119.6 Mb). B6.NZBc1c13 bicongenic
mice were produced by intercrossing B6.NZBc1 and B6.NZBc13
mice and selecting for homozygous NZB chromosome 1 and 13
intervals in successive crosses. Typing of all polymorphic markers
(spaced on average ,5–6 Mb apart) in the NZB chromosome 1
and 13 intervals of bicongenic mice was identical to that of the
parental monocongenic mice. The mice were housed in micro-
isolators in the animal facility at the Toronto Western Hospital
(Toronto, Canada) and were specific-pathogen free. All of the
mice that were examined in this study were female.
Flow cytometry analysis
RBC-depleted splenocytes, bone marrow cells, or BMDC
(5610
5) were incubated with 10 mg/ml mouse IgG (Sigma-Aldrich,
St Louis, MO) for 15 min to block Fc receptors and stained with
various combinations of directly-conjugated mAbs. Following
washing,allophycocyanin-conjugatedstreptavidin(BDBiosciences,
San Diego, CA) was used to reveal biotin-conjugated Ab staining.
Dead cells were excluded by staining with 0.6 mg/ml propidium
iodide(PI;Sigma-Aldrich).Forintracellularstaining,cellswerefixed
and permeabilized using Cytofix/Cytoperm (BD Biosciences), and
washed and stained in Perm/Wash buffer (BD Biosciences),
according to the manufacturer’s protocol. Flow cytometry of the
stained cells was performed using a FACSCalibur or LSRII (BD
Biosciences, Mountain View, CA) and analyzed using Cell Quest
Pro (BD Biosciences) or FlowJo (Treestar) software. Live cells were
gatedonthebasisofPIexclusionandscatteringcharacteristics,with
10,000 or 25,000 events being acquired for each sample. The
following directly conjugated mAbs were purchased from BD
Biosciences:biotinconjugatedanti-CD11c(N418),-CD11b(Mac1),
-CD4 (L3T4), -CD8 (53-6.7), and -CD62L (MEL-14); PerCP
conjugatedanti-B220(30-F11);PEconjugatedanti-B7.1(16-10A1),
-B7.2 (GL1), -IA/IE (M5/114.15.2), -CD3 (145-2C11), -CD23
(B3B4), -IgM
b (AF6-78), -CD69 (H1.2F3), -CD44 (IM7), -ICAM-1
(3E2), -NK1.1 (PK136), and -CD4 (H129.19); FITC conjugated
anti-CD3 (145-2C11), -CD4 (L3T4), -CD8 (53-6.7), -CD21/CD35
(7G6), -CD25 (7D4), -B220 (RA3-6B2), and -CD11c (N418); PE-
Cy7 conjugated anti-CD19 (1D3); Pacific Blue conjugated anti-
B220 (RA3-6B2); and APC-Cy7 conjugated anti-CD11b (M1/70).
Allophycocyaninconjugatedanti-CD9(eBioKMC8)waspurchased
fromeBioscience,andPacificBlueanti-SiglecH(551)andAPC-Cy7
anti-IA/IE (M5/114.15.2) were purchased from BioLegend.
Biotinylated antibiodies were revealed with streptavidin conjugated
with allophycocyanin or PerCP from BD Biosciences. FITC and
biotin conjugated PDCA-1 (Miltenyi Biotec) was a generous gift
from Dr. Eleanor Fish. FITC anti-CD62L (MEL-14) and anti-
CD11b (M1/70.15) were purchased from Cedarlane (Hornby,
Ontario, Canada). All isotype controls, with the exception of
hamster IgG controls (BD Biosciences), were purchased from
Cedarlane.
Measurement of Ab production
Serum levels of IgM, IgG, and IgA anti-chromatin, -dsDNA
and -ssDNA Ab were measured by ELISA. ssDNA was prepared
by boiling dsDNA (isolated from calf thymus DNA) for 10 min
and quick cooling on ice for 2 minutes. H1-stripped chromatin
was prepared from chicken RBC, as previously described [40].
ELISA plates were coated overnight with chromatin (8 mg/ml),
dsDNA (40 mg/ml) or ssDNA (20 mg/ml) diluted in PBS at 4uC.
The plates were then washed with 0.05% Tween 20/PBS, and
blocked with 2% BSA/PBS for 1 h at room temperature. After
further washing, serum samples, diluted 1/100 in 2% BSA/Tween
20/PBS, were added. Bound Ab were detected using alkaline
phosphatase-conjugated anti-IgG, -IgM or -IgA Ab (Caltag,
Burlingame, CA) as secondary reagents. For measurement of
total IgM, IgG, and IgA, plates were coated with goat anti-mouse
IgM or IgG (Jackson ImmunoResearch, West Grove, PA, USA) or
rat anti-mouse IgA (BD Biosciences) respectively, and the serum
was diluted 1/1000. The amount of bound IgM, IgG or IgA was
calculated from a standard curve using purified class-specific
controls, and the Ab concentration was calculated from a plot of
concentration versus absorbance.
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+
splenic DC isolation
Bone marrow cells were isolated by flushing femurs of 8–12
week-old mice. After RBC lysis, ex vivo cells were resuspended to
10
6 cells/mL and cultured for 7 days with recombinant human
Flt3L (20 ng/mL; R&D Systems) in complete RPMI 1640 media
(10% fetal bovine serum (FBS), non-essential amino acids, L-
glutamine, b-mercaptoethanol, penicillin, and streptomycin).
Splenic DC were positively selected using biotin-conjugated anti-
CD11c antibody (N418) and Dynabeads Biotin Binder kit
(Invitrogen), following the manufacturer’s instructions.
TLR stimulation and cytokine blockade
TLR ligands used were imiquimod R837 (2 mM; TLR7), poly
I:C (50 mg/mL; TLR3), CpG ODN 2216 or control (250 nM;
TLR9), CpG ODN 1826 or control (250 nM; TLR9) all from
InvivoGen (San Diego, CA), and LPS (25 mg/mL; Sigma-
Alderich) as a positive control. For splenocytes cultures, 2610
6
cells were cultured in 96-well flat-bottom plates for 48 hours with
various TLR ligands or in media alone (0.5% normal mouse
serum in complete RPMI1640 without FBS). For BMDC cultures,
4610
5 cells were cultured in 96-well flat-bottom plates for 24 or
48 hours with various TLR ligands or in media alone (10% FBS in
complete RPMI 1640). For CD11c
+ splenic DC cultures, 2610
5
cells were cultured in 96-well flat-bottom plates for 24 hours with
CpG 2216 or in media alone (10% FBS in complete RPMI 1640).
To assess IFN-a, IL-10 and TNF-a production following TLR
stimulation, cytokine levels in tissue culture supernatants were
measured by ELISA using commercially available kits as follows:
IFN-a, PBL Biomedical Laboratories (Piscataway, NJ); IL-10,
SABiosciences Corporation (Frederick, MD) or eBioscience (San
Diego, CA); and TNF-a, BD Biosciences or eBioscience. Assays
were performed as per the manufacturer’s recommendations with
the concentration of cytokine calculated from a standard curve of
absorbance versus concentration of recombinant cytokine.
Immunofluorescence staining of tissue sections
Spleens were snap frozen in OCT compound (Sakura Finetek,
Torrance, CA) at the time of sacrifice. Cryostat sections (5 mm)
were fixed in acetone, washed with PBS, and blocked with 5%
normal goat serum/PBS or 5% fetal bovine serum/PBS. Sections
were stained with biotinylated anti-CD11b and FITC anti-CD11c
to detect myeloid DC. BAFF production was assessed by staining
in tandem with rabbit IgG anti-BAFF (Sigma) followed by AMCA-
conjugated goat anti-rabbit IgG Ab (Jackson ImmunoResearch).
Biotin staining was revealed using rhodamine-conjugated strepta-
vidin as a secondary reagent (Molecular Probes, Eugene, OR).
Stained sections were mounted with Mowiol (Calbiochem, La
Jolla, CA) and tissue fluorescence visualized using a Zeiss Axioplan
2 imaging microscope (Oberkochen, Germany). Digital images
were obtained using the manufacturer’s imaging system.
Grading of kidney sections
For immunofluorescence score, kidneys were snap frozen in
OCT compound (Sakura Finetek) and sectioned (3 mm). For
glomerular score, kidneys were fixed in formalin, paraffin
embedded, sectioned (3 mm), and stained with periodic acid-
Schiff. Grading was performed by a renal pathologist (G. Lajoie)
who was blinded as to the strain of origin of the tissue section.
Glomerular staining of kidney sections stained with FITC anti-IgG
was graded by immunofluorescence microscopy. Sections with no
or only trace deposits were graded as 0; those with mesangial
deposits, grade 1 (B more extensive than A); those with mesangial
and segmental capillary wall deposits, grade 2; those with diffuse
mesangial and capillary wall deposits, grade 3; and those with
crescents, grade 4. The grading scale used for glomerular score
using light microscopy was as follows: grade 0, normal glomeruli;
grade 1, mesangial expansion and/or proliferation; grade 2, focal
segmental (endocapillary) proliferative glomerulonephritis; grade
3, diffuse (endocapillary) proliferative glomerulonephritis; and
grade 4, diffuse proliferative glomerulonephritis with crescents.
Measurement of mRNA expression
RNA was purified from splenocytes and bone marrow cells of 8-
month-old mice using the RNeasy Mini Kit (Qiagen, Basel,
Switzerland), treated with DNaseI (Invitrogen, Canada), and
converted to cDNA using the High Capacity cDNA Reverse
TranscriptionKit(AppliedBiosystems,ForsterCity,CA),according
to the manufacturer’s instructions. Quantitative real-time PCR was
performed with SYBR Green Master Mix on a 7900HT Fast Real-
Time PCR System (Applied Biosystems) using default cycling
conditions. Primer sequences were designed to span exon-to-exon
and were as follows: b-actin forward, TTGCTGACAGGATGCA-
GAAG, b-actin reverse, GTACTTGCGCTCAGGAGGAG; baff
forward, CAGGAACAGACGCGCTTTC, baff reverse, GTTGA-
GAATGGCGGCATCC; tnf-a forward, GCCAC-
CACGCTCTTCTGTCT, tnf-a reverse, TCTGGGCCATA-
GAACTGATGAGA; pkr forward, TGAGCGCCCCCCATCT,
pkr reverse, TATGCCAAAAGCCAGAGTCCTT; 29-59 oas for-
ward, TGAGCGCCCCCCATCT, 29-59 oas reverse, CATGACC-
CAGGACATCAAAGG; ifn-a4 forward,
CTTGTCTGCTACTTGGAATGCAA, ifn-a4 reverse, AG-
GAGGTTCCTGCATCACACA; and ifn-b1 forward, TGACG-
GAGAAGATGCAGAAGAG, ifn-b1 reverse CACC-
CAGTGCTGGAGAAATTG. Gene expression was analyzed
using the relative standard curve method and was normalized to
b-actin expression.
Statistics
Statistical significance of comparisons between groups of mice
was determined using the Mann-Whitney non-parametric two-
tailed test with the exception of comparisons between kidney tissue
section grades where Fisher’s exact test was used.
Supporting Information
Table S1 Comparison of the B and T cell phenotypes in
8 month old B6.NZBc1c13 bicongenic mice with
B6.NZBc1 and B6.NZBc13 congenic strains. Results are
mean 6 SD as determined by flow cytometry. Significance level
for comparison of B6.NZBc1c13 mice with other mouse strains
was determined by Mann-Whitney non-parametric test, *p,0.05,
**p,0.005, ***p,0.0005. Numbers of 8 month old mice
examined in each group are shown on the top unless otherwise
indicated in brackets. Numbers shown in bold indicate significant
difference p,0.05 from B6 control mice.
(DOC)
Figure S1 Splenic BAFF expression in B6 and c1c13
bicongenic mice. Cell populations producing BAFF were
characterized by staining with biotinylated anti-CD11b, and FITC
anti-CD11c with rabbit IgG anti-BAFF followed by AMCA-
conjugated goat anti-rabbit IgG Ab. Biotin staining was revealed
using rhodamine-conjugated streptavidin as a secondary reagent.
Arrows indicate the same BAFF-producing CD11b
+CD11c
+ mDC
in each image. The BAFF-producing CD11c
+ cells did not stain
with B220 (data not shown). Scale bar, 100 mm.
(TIF)
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PLoS ONE | www.plosone.org 13 May 2012 | Volume 7 | Issue 5 | e36761Figure S2 IFN-a/b and IFN-a-induced gene expression
in various organs of 2 and 9 month-old B6 and
bicongenic mice. Expression of IFN-a/b and IFN-a-induced
(PKR and 29-59 OAS) genes was measured by qRT-PCR in B6 and
B6.NZBc1c13 (c1c13) spleen (A) and bone marrow cells (B) at 2
months of age, and in the bone marrow cells (C) and kidneys (D) at
9 months of age. Relative mRNA expression of genes of interest
normalized to b-actin mRNA expression. Each point represents
the determination from an individual mouse. The p values for
significant differences between B6.NZBc1c13 and B6 controls by
Mann-Whitney non-parametric test were shown, *p,0.05.
(TIF)
Figure S3 Similar levels of cytokine production, but
reduced B7.2 expression in myeloid dendritic cells from
bicongenic mice upon TLR stimulation. BMDC from 8–12
week-old mice were expanded in the presence of Flt3L for 7days
and then cultured in the presence or absence of imiquimod R837,
poly I:C, CpG 1826, CpG 2216 and LPS. (A) IFN-a, (B) TNF-a,
and (C) IL-10 production in the culture supernatant was measured
by ELISA. Each symbol represents the determination from an
individual mouse, with background levels of cytokine with media
alone subtracted. MFI for B7.2 expression on (D) CD11c
+ total
dendritic cells, (E) CD11c
+B220
+CD11b
2 plasmacytoid dendritic
cells, and (F) CD11c
+CD11b
+B220
2 myeloid dendritic cells, as
determined by flow cytometry. The p values for significant
differences are shown, where *p,0.05,* * p,0.005, ***p,0.0005,
and were determined by the Mann-Whitney non-parametric test.
Horizontal lines indicate the mean for each population examined.
(TIF)
Figure S4 Examination of the splenic age-associated B
cell population. (A) Similar proportion of contaminating IgM
+
CD19
+ CD11b
int cells within the CD11c
+ B220
+ cell population
across all strains and age groups. (B) Elevated levels of pDC in
older bicongenic mice gated as CD11c
+ B220
+ CD11b
2 and
excluding CD11b
int ABC subset. (C) Increased proportion of
ABCs is seen only in older bicongenic mice. ABCs were gated as
IgM
+ CD19
+ B220
+ CD11c
int CD11b
int and are expressed as a
percentage of live cells. (D) Representative contour plots showing
the gating and proportion of CD11c
int CD11b
int cells as a
percentage of live cells in young and old B6 and bicongenic mice.
The p values for significant differences are shown, where *p,0.05,
***p,0.0005, and were determined by the Mann-Whitney non-
parametric test.
(TIF)
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